Investment Summary |
|
|---|---|
| Date | 2020-04-22 |
| Target | FoRx Therapeutics |
| Sector | Life Science |
| Investor(s) |
EQT Life Sciences
Pfizer |
| Deal Type | Venture |
SEARCH BY
| Category | Growth Capital Firm |
|---|---|
| Founded | 1987 |
| PE ASSETS | 3.5B EUR |
| Size | Large |
| Type | Sector Focused |
EQT Life Sciences (formerly Life Science Partners) is a private investment firm focused on growth and venture capital financing for life sciences and healthcare companies. The Firm targets early to mid?stage companies in sectors such as therapeutics, medical devices, diagnostics, healthtech, and biotech. EQT Life Sciences was formed in 1986 and is headquartered in Amsterdam, the Netherlands.
| DEAL STATS | # |
|---|---|
| Overall | 26 of 47 |
| Sector: Life Science M&A | 14 of 30 |
| Type: Venture M&A Deals | 22 of 39 |
| Country: Switzerland M&A | 2 of 3 |
| Year: 2020 M&A | 1 of 7 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-09-05 |
iSTAR Medical
Wavre, Belgium iSTAR Medical is a private medical device company developing novel ophthalmic implants for the treatment of glaucoma. iSTAR Medical was founded in 2010 and is based in Wavre, Belgium. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-04-30 |
Kiadis Pharma
Amsterdam, Netherlands Kiadis Pharma is a clinical stage biopharmaceutical company pioneering a proprietary cell-based, personalized therapy for patients with blood cancers and related disorders, an area of significant unmet medical need.Kiadis Pharma’s unique and powerful platform technology has led to an initial experimental product, ATIR™, which has already been clinically tested on sixty patients. Kiadis Pharma is based in Amsterdam, Netherlands. |
Buy | - |
| Category | Company |
|---|---|
| Founded | 1849 |
| Sector | Life Science |
| Employees | 81,000 |
| Revenue | 63.6B USD (2024) |
Pfizer is a global pharmaceutical company that is involved in the discovery, development, manufacture, and marketing of a wide range of healthcare products, including medicines and vaccines. The company's portfolio includes treatments across a broad spectrum of areas such as oncology, cardiology, neurology, and infectious diseases, among others. Pfizer was founded in 1849 and is based in New York, New York.
| DEAL STATS | # |
|---|---|
| Overall | 35 of 46 |
| Sector: Life Science M&A | 31 of 41 |
| Type: Venture M&A Deals | 2 of 2 |
| Country: Switzerland M&A | 3 of 3 |
| Year: 2020 M&A | 1 of 3 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-01-13 |
Pfizer - CK 1 Business
New York, New York, United States Pfizer, Inc. - CK 1 Business is a novel CNS-penetrant small molecule inhibitor of casein kinase 1 (CK1), for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases. |
Sell | $75M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-07-30 |
Cerevel
Cambridge, Massachusetts, United States Cerevel is a biopharmaceutical company focused on developing drug candidates to treat disorders of the central nervous system (CNS). The company has a portfolio of pre-commercial neuroscience assets, which include three clinical-stage compounds and several pre-clinical compounds designed to target a broad range of CNS disorders including Parkinson’s, Alzheimer’s, epilepsy, schizophrenia, and addiction. Cerevel was formed in 2018 and headquartered in Cambridge, Massachusetts. |
Sell | - |
